Radiprodil

Radiprodil (RGH-896) is an orally active and selective NMDA NR2B antagonist. A potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions[1].

Product Specifications

CAS Number

[496054-87-6]

Product Name Alternative

RGH-896

UNSPSC

12352005

Hazard Statement

H302, H319, H372, H410

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Radiprodil.html

Purity

99.16

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C2NC(OC2=C1)=O)C(N3CCC(CC4=CC=C(F)C=C4)CC3)=O

Molecular Formula

C21H20FN3O4

Molecular Weight

397.40

Precautions

H302, H319, H372, H410

References & Citations

[1]Mony L, et al. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol. 2009 Aug;157 (8) :1301-17.|[2]Rammes G, et al. The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (Aβ) species on long-term potentiation (LTP) . Neuropharmacology. 2018 Sep 15;140:184-192.|[3]Mullier B, et al. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors. Neuropharmacology. 2017 Sep 1;123:322-331.